Organic India launches single ingredient Moringa products in US

New Drug Approvals

Moringa oleifera

The Drumstick Plant

http://miracletrees.org/

08 February 2013, Organic India, a manufacturer of herb-based functional supplements, has launched organic single ingredient Moringa products in the US.

Available in both capsule and powder formulations, the product made from powdered leaves of Moringa oleifera tree contains vitamin A, B1, B3, B12, iron, magnesium, potassium, amino acids, and polyphenols and is used for restoring internal imbalances.

Organic India national sales manager Heather Henning said the ancient therapeutic Moringa oleifera plant has been used for years and has seen increasing popularity amongst mainstream consumers worldwide.

Moringa oleifera leaf powdermoringa

“Millions of people globally use Moringa for essential nutrition — now, the US distribution channel will have access to this extraordinary plant with USDA organic certification,” Henning added.

The company said Moringa supplement, which has more B12 than steak, more vitamin A than eggs, and more calcium than milk, will be unveiled to the public…

View original post 885 more words

Natrol, Inc. Revitalizes Hair Technology with NuHair® FOAM, a Natural Solution for Male and Female Hair Rejuvenation

New Drug Approvals

February 21, 2013, Natrol, Inc., a global leader in the nutrition industry and trusted manufacturer and marketer of superior quality supplements, has raised the bar for hair technology and created an alternate and innovative method to enhance hair rejuvenation among men and women with NuHair® FOAM. The product is hitting the marketplace following Natrol’s tablet hair-rejuvenation product being named the #1 selling supplement for hair growth.

NuHair® FOAM, now available at Walgreens nationwide, joins the NuHair line of dietary supplements that includes: Hair Regrowth Tablets designed for both men and women, Thinning Hair Serum, and DHT Blocker. The productwas specifically created to protect against follicle damage, graying hair, and bring nourishment to the scalp and revitalize each strand to promote fuller, beautiful hair. It is also a 2-in-1 product, which has a light hold for styling.

“Natrol believes that hair rejuvenation begins at the root, and we’re thrilled to…

View original post 220 more words

Top 20 Best-Selling Drugs Approved and Launched During 2012

New Drug Approvals

Genetic Engineering & Biotechnology News | www.genengnews.com

Biotechnology from bench to business

Top 20 Best-Selling Drugs Approved and Launched During 2012

What new medicines are shaking things up?

read all this at http://www.genengnews.com/insight-and-intelligence/top-20-best-selling-drugs-approved-and-launched-during-2012/77899791/

have a good reading

View original post

Daiichi Sankyo enrolls first patient in Nimotuzumab Phase 3 clinical trials

New Drug Approvals

Nimotuzumab

25 April 2013
Daiichi Sankyo Company, Limited announced today that the first patient has been enrolled in two pivotal phase 3 clinical trials of nimotuzumab (DE-766), a recombinant humanized monoclonal antibody targeting the Epidermal Growth Factor Receptor (EGFR), which is being evaluated for the treatment of patients diagnosed with lung cancer and with gastric cancer.

About Phase 3 Clinical Trials for Lung Cancer

The phase 3 clinical trial is a multicenter, randomized, double-blind, placebo-controlled study investigating nimotuzumab for the first-line therapy in patients with unresectable and locally advanced squamous cell lung cancer. The patients will receive either nimotuzumab in combination with concurrent chemoradiotherapy or placebo in combination with concurrent chemoradiotherapy. The primary endpoint is overall survival (OS), and the secondary endpoints are progression free survival (PFS) and safety. Approximately 420 patients are planned to be enrolled at approximately 60 clinical centers in Japan. Additional details of the trial are…

View original post 435 more words

Daiichi Sankyo enrolls first patient in Nimotuzumab Phase 3 clinical trials

New Drug Approvals

Nimotuzumab

25 April 2013
Daiichi Sankyo Company, Limited announced today that the first patient has been enrolled in two pivotal phase 3 clinical trials of nimotuzumab (DE-766), a recombinant humanized monoclonal antibody targeting the Epidermal Growth Factor Receptor (EGFR), which is being evaluated for the treatment of patients diagnosed with lung cancer and with gastric cancer.

About Phase 3 Clinical Trials for Lung Cancer

The phase 3 clinical trial is a multicenter, randomized, double-blind, placebo-controlled study investigating nimotuzumab for the first-line therapy in patients with unresectable and locally advanced squamous cell lung cancer. The patients will receive either nimotuzumab in combination with concurrent chemoradiotherapy or placebo in combination with concurrent chemoradiotherapy. The primary endpoint is overall survival (OS), and the secondary endpoints are progression free survival (PFS) and safety. Approximately 420 patients are planned to be enrolled at approximately 60 clinical centers in Japan. Additional details of the trial are…

View original post 435 more words

GSK announces regulatory submission for umeclidinium monotherapy in European Union

New Drug Approvals

 

Umeclidinium bromide

http://www.ama-assn.org/resources/doc/usan/umeclidinium-bromide.pdf

26 April 2013
GlaxoSmithKline plc  today announced the submission of a regulatory application in the European Union for the investigational once-daily medicine, umeclidinium bromide (UMEC), for patients with chronic obstructive pulmonary disease (COPD).

UMEC is an investigational bronchodilator molecule (formerly known as GSK573719), a long-acting muscarinic antagonist (LAMA), administered using the ELLIPTA™ inhaler.

A Marketing Authorisation Application (MAA) for UMEC monotherapy (55 mcg delivered dose) has been submitted to the European Medicines Agency (EMA), for a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.

Regulatory filings for UMEC monotherapy are imminent in the US and planned in other countries during the course of 2013.

View original post